Recent Updates
Recently added Catalysts
DARE Positive Sentiment

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Daré Bioscience has reported its second quarter results for 2026, highlighting the launch of Flora Sync LF5™, which started generating revenue in July. The company is also advancing its DARE to PLAY™ Sildenafil Cream, with expectations for national dispensing and initial revenue in the third quarter of 2026. Prescriptions and preorders for the cream are already being accepted.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of Flora Sync LF5™ marks a successful commercial entry.
  • DARE to PLAY™ Sildenafil Cream is progressing well towards revenue generation.
  • Initial revenue generation from Flora Sync LF5™ began in July.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~7 mo
Medium dilution risk
Lead asset
Lopinavir / ritonavir
Phase 2 · Human Papilloma Virus (HPV)

Full Press Release Details

Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions and preorders already being accepted

Frequently Asked Questions

What is Flora Sync LF5™?

Flora Sync LF5™ is Daré Bioscience's first directly commercialized product.

When did Flora Sync LF5™ start generating revenue?

Flora Sync LF5™ began generating revenue in July 2026.

What is the status of DARE to PLAY™ Sildenafil Cream?

DARE to PLAY™ Sildenafil Cream is progressing towards national dispensing and revenue.

Are prescriptions for DARE to PLAY™ being accepted?

Yes, prescriptions and preorders for DARE to PLAY™ are currently being accepted.

ShareAdd on Google
Tags: DARE Viatris Investor Conferences Healthcare Daré Bioscience Flora Sync LF5 DARE to PLAY Sildenafil Cream women's health
Last updated: Aug 13, 2026

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~7 mo
Medium dilution risk
Lead asset
Lopinavir / ritonavirPhase 2
Human Papilloma Virus (HPV) →